2025 DIA Global Annual Meeting: The Role of Leadership in Shaping the Future of Clinical Research
In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, reflects on the importance of leadership to drive progress in clinical research amid evolving regulatory and funding challenges.
ACT: Could you elaborate on the importance of leadership in this current landscape of clinical research being impacted by regulatory and administrative shifts?
Pierce: The panel we had this morning for the opening session I thought was incredible, because you had the FDA, EMA, MHRA all sitting there together with a patient and also having a scientific publisher and a few others on the panel, to be able to debate the value of academic research, and funding cuts, and how is that going to impact science long term? How do these really novel discoveries happen? They're happening in academic labs, so being able to provide a platform for those conversations to happen by having sometimes a little bit of conflict and debate. Our mission has always been to be that neutral space, but I think being neutral really means bringing all of those varied perspectives together and making sure that the conversation, the dialog, continues and evolves. People don't grow if you don't challenge and push each other, and I think that's really what DIA, our platform allows us to do, bring together the best of ideas, but bring together opposing ideas, and make sure that at the end of the day, it's really for the advancement of care for patients.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
